Baidu's Reinvention Leaves Investors Searching for Profits

Related Link: 

Baidu is investing heavily in new services to keep pace with rivals, eating up profits in the process.

Dutch Law Sinks Drug Tie-Up

Related Link: 

When Mylan moved its legal home to the Netherlands it gained not just tax savings, but a Dutch corporate rule book that gave it more levers to resist takeovers, such as Teva’s $40 billion proposal.

Allergan's Healthy Price May Come With Side Effects

Related Link: 

While investors are excited about Allergan’s pursuit of more deals, they have to hope it doesn’t bite off more than it can chew.

U.S. Durable Orders Up 3.4% in June

Related Link: 

New orders for durable goods rose a seasonally adjusted 3.4% in June from a month earlier, the Commerce Department said.

Teva's Allergan Deal Looks a Healthier Mouthful

Related Link: 

Teva’s $40.5 billion deal to buy Allergan’s generics business looks a lower risk option than its hostile pursuit of Mylan.

China Stock-Market Recovery Goes All Wobbly

Related Link: 

The dam Beijing hastily built to hold back the selloff has sprung a major leak.

A More Durable Spending Plan for Businesses

Related Link: 

Energy-sector weakness has weighed on business investment, but with the industry showing signs of stability, capital spending should pick up.

Lawyer Emails Put Visa, MasterCard Settlement at Risk

Related Link: 

The discovery of a trove of emails between two opposing lawyers is threatening to scuttle the $6 billion class-action antitrust settlement.

Fed Officials May Offer More Clarity on Rates

Related Link: 

Central bank officials are likely to emerge from their meeting Wednesday with short-term interest rates still pinned near zero, though they could send hints that they’re getting closer to raising the rates. Chairwoman Yellen has emphasized she expects higher U.S. borrowing costs before year-end.

UBS Leads on Capital But Payouts Won't Come Quick

Related Link: 

The Swiss bank has the best capital ratio among large global banks but it still faces regulatory hurdles.

Syndicate content